USPTO serial 90039971
ASCENTAGE PHARMA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 23, 2021
- Examiner
- LINDEMYER, ANKHI MUKHERJEA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ASCENTAGE PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Jiangsu Ascentage Biomed Development Inc.
Taizhou, Jiangsu, CN
Other trademarks owned by Jiangsu Ascentage Biomed Development Inc.
Jiangsu Ascentage Biomed Development Inc.
Taizhou, Jiangsu, CN
Other trademarks owned by Jiangsu Ascentage Biomed Development Inc.
Jiangsu Ascentage Biomed Development Inc.
Taizhou, Jiangsu, CN
Other trademarks owned by Jiangsu Ascentage Biomed Development Inc.
ASCENTAGE PHARMA (SUZHOU) CO., LTD.
SUZHOU, CN
Other trademarks owned by ASCENTAGE PHARMA (SUZHOU) CO., LTD.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kathryn E. Smith
Kathryn E. Smith Wood Herron & Evans LLP600 Vine StreetSuite 2800Cincinnati, OH 45202Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for dental purposes; chemical preparations for medical purposes for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antibiotics; medicine for injection for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; medicinal tablets, for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bulk drugs, namely, pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease sold in bulk; biochemical medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antiseptics; collyrium; suppositories being pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; plasters for medical purposes; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; medicated candy; candy for medical purposes; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic preparations adapted for medical use; oil solutions, namely, medicinal oils; mineral food supplements; nutritional supplements; medicines for human purposes, namely, pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bacterial poisons; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biological preparations for medical purposes for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical preparations for pharmaceutical purposes, for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease | ACTIVE | — |
| 042 | Analysis of the mode of action of chemical combinations on animals; scientific research for medical purposes in the area of cancerous diseases; conducting early evaluations in the field of new pharmaceuticals; pharmaceutical research services; scientific investigations for medical purposes; chemical analysis services; biochemical research and analysis; chemical research services; working on and evaluation of chemical analyses; chemical research and analysis; working on and evaluation of chemical syntheses; chemical analysis; chemistry services in the nature of chemist services; chemical research; cosmetics research; structural and functional analysis of genomes; stem cell research services; biotechnology research; blood analysis services; genetic screening for scientific research purposes; biological cloning services; research and development services in the field of antibodies; genetic testing for scientific research purposes; bacteriological research and analysis; biomedical research services; medical research; drug discovery services; medical laboratory services; development of pharmaceutical preparations and medicines; medical research services; biological research and analysis; bacteriological research; biological research; conducting clinical trials for others; computer programming in the medical field; pharmaceutical product evaluation; research on the subject of pharmaceuticals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Jiangsu Ascentage Biomed Development Inc.
- Other trademarks owned by Jiangsu Ascentage Biomed Development Inc.
- Other trademarks owned by Jiangsu Ascentage Biomed Development Inc.
- Other trademarks owned by ASCENTAGE PHARMA (SUZHOU) CO., LTD.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ASCENTAGE PHARMA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 21, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 21, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Aug 21, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 21, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 21, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 21, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 2, 2025 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Nov 23, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 7, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 7, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 18, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 3, 2021 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Jul 30, 2021 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Jul 28, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 28, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 28, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 28, 2021 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 12, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 12, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 12, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 23, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 3, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 3, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 2, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 20, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 20, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 20, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 14, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 5, 2020 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Aug 4, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 27, 2020 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jul 27, 2020 | ALIE | ASSIGNED TO LIE | — |
| Jul 13, 2020 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jul 10, 2020 | NWAP | NEW APPLICATION ENTERED | — |